bitFlyer, a Japanese crypto exchange, has experienced delays in crediting incoming Stellar Lumens (XLM) deposits since October 19 due to restricted access to the official Stellar Development Foundation API. This issue affects when XLM deposits appear in customer accounts, though users can still send XLM and trade other cryptocurrencies. bitFlyer is working on an alternative method to credit deposits but has not provided a timeline for resolution. Customers trading XLM/JPY need XLM credited in their accounts, and the exchange will update users once normal crediting resumes.
Stellar Lumens (XLM) deposit delays at bitFlyer provide context for cryptocurrency market activity. For readers following crypto broadly, here is Pluang's market snapshot as of Oct 21, 2026 05:11 WIB: Out of 50 major cryptocurrencies priced on Pluang, 44 rose and 5 fell today. Notable movers include SNX at Rp4.060 with a 4.96% increase and a typical hold time of 70 days, GRT at Rp449 up 4.87% with 94 days typical hold time, and AAVE at Rp2.793.220 rising 4.77%.
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
